Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival

BackgroundAdding pembrolizumab, an anti-PD-1 antibody approved for treatment of head and neck squamous cell carcinoma (HNSCC) to neoadjuvant (induction-) chemotherapy utilizing docetaxel and cisplatin (TP) followed by radiotherapy may improve outcome in larynx organ-preservation (LOP) that is invest...

Full description

Saved in:
Bibliographic Details
Main Authors: Jana Wellhausen, Louisa Röhl, Michael Berszin, Irene Krücken, Veit Zebralla, Markus Pirlich, Matthaeus Stoehr, Susanne Wiegand, Andreas Dietz, Theresa Wald, Gunnar Wichmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
PD-1:PD-L1 immune-checkpoint inhibitor (ICI) pembrolizumab
local and locoregional advanced head and neck squamous cell carcinoma (HNSCC)
neoadjuvant (induction) chemotherapy
predictive assay for chemoresponse-evaluation
biomarker research
monocyte chemoattractant protein 1 (MCP-1
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1473897/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1473897/full

Similar Items